Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $2,000 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $30 | $1,987 | $31 | $0 |
| Gross Profit | -$30 | $13 | -$31 | $0 |
| % Margin | – | 0.7% | – | – |
| R&D Expenses | $1,034 | $2,206 | $1,461 | $2,242 |
| G&A Expenses | $1,455 | $2,307 | $2,134 | $847 |
| SG&A Expenses | $1,455 | $2,307 | $2,134 | $847 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,489 | $4,513 | $3,595 | $3,089 |
| Operating Income | -$2,489 | -$4,500 | -$3,595 | -$3,089 |
| % Margin | – | -225% | – | – |
| Other Income/Exp. Net | $15,623 | -$2,558 | -$6,188 | -$15,420 |
| Pre-Tax Income | $13,134 | -$7,058 | -$9,783 | -$18,509 |
| Tax Expense | -$126 | $584 | $416 | $1,133 |
| Net Income | $13,288 | -$7,642 | -$10,189 | -$19,619 |
| % Margin | – | -382.1% | – | – |
| EPS | 0.32 | -0.19 | -0.26 | -0.48 |
| % Growth | 268.4% | 26.9% | 45.8% | – |
| EPS Diluted | 0.31 | -0.19 | -0.26 | -0.48 |
| Weighted Avg Shares Out | 41,743 | 41,229 | 39,920 | 40,897 |
| Weighted Avg Shares Out Dil | 42,609 | 41,229 | 39,920 | 40,897 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15,366 | $0 | -$19,322 | $0 |
| Interest Expense | $0 | $2,558 | -$15,420 | $15,420 |
| Depreciation & Amortization | $30 | $30 | $31 | $52 |
| EBITDA | $13,164 | -$4,470 | -$9,752 | -$3,037 |
| % Margin | – | -223.5% | – | – |